New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
09:04 EDTALXAAlexza Pharmaceuticals receives marketing authorization for Adasuve in EU
Alexza Pharmaceuticals announced that the European Commission has granted marketing authorization for Adasuve. In the European Union, Adasuve, 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects.
News For ALXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
09:07 EDTALXAAlexza Pharmaceuticals and Ferrer expand Adasuve partnership
Alexza Pharmaceuticals announced that they have amended their agreement for ADASUVE. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries. Ferrer and Alexza have agreed that Ferrer will purchase 2M shares of Alexza common stock for $4.00 per share, thereby becoming the company's largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use